Migoutine (Colchicine)

Colchicine, the active ingredient in Migoutine, is an alkaloid (microtubule inhibitor) presented as an oral tablet for oral use. It reduces inflammation during acute gout flares, helps prevent recurrent gout attacks, and is used for long‑term management of familial Mediterranean fever in adult patients.

GNH USA supplies Migoutine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels aligned to EU regulatory standards. The product complies with EU pharmacopeial specifications and is available for bulk procurement.

Colchicine is used to manage inflammatory conditions related to crystal deposition and hereditary autoinflammatory disorders.

Acute gout flares: rapid reduction of joint inflammation and pain during an attack. Prophylaxis of gout attacks: prevention of recurrent gout episodes when used continuously. Familial Mediterranean fever: control of febrile attacks and serosal inflammation in affected individuals.

Colchicine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, abdominal pain, or diarrhoea. - Diarrhoea: frequent loose stools, sometimes leading to dehydration. - Abdominal cramping: discomfort in the stomach area. - Loss of appetite: reduced desire to eat. - Headache: mild to moderate head pain. - Metallic taste: altered taste sensation.

Serious or Rare Side Effects: - Myelosuppression: bone‑marrow depression causing low blood counts. - Neuromuscular toxicity: muscle weakness or neuropathy, especially with renal impairment. - Severe hypersensitivity: rash, fever, or anaphylaxis. - Multi‑organ failure: rare but life‑threatening systemic toxicity.

When prescribing colchicine, clinicians should consider several precautionary measures to minimise risk.

Renal function: adjust dose or avoid use in severe renal impairment. Hepatic function: monitor liver enzymes and use caution in hepatic disease. Drug interactions: review concomitant medications that affect colchicine metabolism. Pregnancy and lactation: avoid use unless benefits outweigh potential risks. Gastrointestinal disorders: use with caution in patients with pre‑existing GI disease. Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Colchicine interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may cause colchicine toxicity. - P‑glycoprotein inhibitors (e.g., cyclosporine, verapamil): increase colchicine levels. - Statins (especially simvastatin) at high doses: risk of myopathy and rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Digoxin: colchicine may increase digoxin concentrations. - Macrolide antibiotics (e.g., azithromycin): moderate increase in colchicine exposure. - NSAIDs: additive gastrointestinal irritation risk.